ArticleProceedings of the National Academy of Sciences of the United States of America1993
p53 gene mutations and protein accumulation in human ovarian cancer.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 299 citations in OpenAlex.
- TP53 mutations and MDM2 polymorphisms in breast and ovarian cancers: amelioration by drugs and natural compounds.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- The Clinical Significance ofInternational journal of molecular sciences · 2024Article
- Identification of KIF23 as a prognostic signature for ovarian cancer based on large-scale sampling and clinical validation.American journal of translational research · 2020Article
- CeModule: an integrative framework for discovering regulatory patterns from genomic data in cancer.BMC bioinformatics · 2019Article
- TMEFF1 overexpression and its mechanism for tumor promotion in ovarian cancer.Cancer management and research · 2019Article
- Effect of Mutant p53 Proteins on Glycolysis and Mitochondrial Metabolism.Molecular and cellular biology · 2017Article
- The Putative Role ofJournal of Cancer · 2017Review
- Granulosa Cell-Specific Brca1 Loss Alone or Combined with Trp53 Haploinsufficiency and Transgenic FSH Expression Fails to Induce Ovarian Tumors.Hormones & cancer · 2015Article
- A computational approach to identifying gene-microRNA modules in cancer.PLoS computational biology · 2015Article
- Expression and functions of galectin-7 in ovarian cancer.Oncotarget · 2014Article
- Ovarian cancer biomarker discovery based on genomic approaches.Journal of cancer prevention · 2013Review
- Chaperone-mediated autophagy degrades mutant p53.Genes & development · 2013Article
- Contribution of BubR1 to oxidative stress-induced aneuploidy in p53-deficient cells.Cancer medicine · 2013Article
- Establishment of a new representative model of human ovarian cancer in mice.Journal of ovarian research · 2013Article
- Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.Cellular and molecular life sciences : CMLS · 2012Review
- An inconspicuous fallopian-tube carcinoma clinically manifested as a rectovaginal septal tumor: a pitfall for diagnosis and treatment.International journal of clinical oncology · 2011Article
- Microenvironment and pathogenesis of epithelial ovarian cancer.Hormones & cancer · 2010Review
- Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.The Journal of pathology · 2010Article
- Precursors of endometrial and ovarian carcinoma.Virchows Archiv : an international journal of pathology · 2010Review
- Ovarian cancer pathogenesis: a model in evolution.Journal of oncology · 2010Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Mutations of the p53 gene on chromosome 17p are a common genetic change in the malignant progression of many cancers. We have analyzed 38 malignant tumors of ovarian or peritoneal müllerian type for evidence of p53 variations at either the DNA or protein levels. Genetic studies were based on single-strand conformation polymorphism analysis and DNA sequencing of exons 2 through 11 of the p53 gene; mutations were detected in 79% of the tumors. These data show a statistically significant association between mutations at C.G pairs and a history of estrogen therapy. Two of 20 patients whose normal tissue could be studied carried germ-line mutations of p53. Immunohistochemical analysis of the p53 protein was carried out using monoclonal antibody PAb1801. Ninety-six percent of the missense mutations were associated with abnormal accumulation of p53 protein, but nonsense mutations, a splicing mutation, and most deletions did not result in p53 protein accumulation. A statistically significant association between p53 protein accumulation in poorly differentiated stage III serous carcinomas and small primary tumor size at diagnosis was found, perhaps suggesting that p53 protein accumulation accelerates the metastatic spread from a primary tumor. Overall, our findings indicate that alterations of p53 play a major role in ovarian cancer, including predisposition to the disease in some patients, and suggest a possible mechanism for somatic mutations leading to this cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.